BoNT/DC (C345)

Sequence

BLAST     FASTA    
MTWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGSDVEIIPQIERLQLREKALGHYKDIAKRLNNINKTIPSSWSSNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSKHYLPVFANILDDNIYTIINGFNLTTKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCLRLTRNSRDDSTCIQVKNNTLPYVADKDSISQEIFESQIITDETNVENYSDNFSLDESILDAKVPTNPEAVDPLLPNVNMEPLNVPGEEEVFYDDITKDVDYLNSYYYLEAQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSAIIPYIGPALNIGNSALRGNFKQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHISYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLKTKTELINLIDSHNIILVGEVDRLKAKVNESFENTIPFNIFSYTNNSLLKDMINEYFNSINDSKILSLQNKKNTLMDTSGYNAEVRVEGNVQLNPIFPFDFKLGSSGDDRGKVIVTQNENIVYNAMYESFSISFWIRINKWVSNLPGYTIIDSVKNNSGWSIGIISNFLVFTLKQNENSEQDINFSYDISKNAAGYNKWFFVTITTNMMGNMMIYINGKLIDTIKVKELTGINFSKTITFQMNKIPNTGLITSDSDNINMWIRDFYIFAKELDDKDINILFNSLQYTNVVKDYWGNDLRYDKEYYMINVNYMNRYMSKKGNGIVFNTRKNNNDFNEGYKIIIKRIRGNTNDTRVRGENVLYFNTTIDNKQYSLGMYKPSRNLGTDLVPLGALDQPMDEIRKYGSFIIQPCNTFDYYASQLFLSSNATTNRLGILSIGSYSFKLGDDYWFNHEYLIPVIKIEHYASLLESTSTHWVFVPASE

Properties

MW: 147,325.98 Da
No. of AA: 1285
Abs 0.1% (g/L): 1.256
pI: 5.33
NCBI ID: ABP48747
UniprotKB: A5JGM8
Strains: OFD13, OFD04, VPI 5995, OFD17, OFD12, OFD09, NCIB 10619, OFD08, OFD28, 08084L-60 Eppendorf, OFD05, OFD32, OFD33, 193_09, 1276_DC, 1274_DC, 1275_DC
Associated Proteins:
Notes:

Associated Publications

Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.
Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA. (2007). Vaccine
DOI:   PMID: 17395341

Characterization of the D/C mosaic neurotoxin produced by Clostridium botulinum associated with bovine botulism in Japan.
Nakamura K, Kohda T, Umeda K, Yamamoto H, Mukamoto M, Kozaki S. (2010). Vet. Microbiol.
DOI: 10.1016/j.vetmic.2009.07.023   PMID: 19720474

A lipid-binding loop of botulinum neurotoxin serotypes B, DC and G is an essential feature to confer their exquisite potency.
Stern D, Weisemann J, Le Blanc A, von Berg L, Mahrhold S, Piesker J, Laue M, Luppa PB, Dorner MB, Dorner BG, Rummel A. (2018). PLoS Pathog.
DOI: 10.1371/journal.ppat.1007048   PMID: 29718991

Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC.
Zhang S, Berntsson RP, Tepp WH, Tao L, Johnson EA, Stenmark P, Dong M. (2017). Nat Commun
DOI: 10.1038/s41467-017-01534-z   PMID: 29158482

Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins.
Peng L, Berntsson RP, Tepp WH, Pitkin RM, Johnson EA, Stenmark P, Dong M. (2012). J. Cell. Sci.
DOI: 10.1242/jcs.103564   PMID: 22454523

Crystal structures of botulinum neurotoxin DC in complex with its protein receptors synaptotagmin I and II.
Berntsson RP, Peng L, Svensson LM, Dong M, Stenmark P. (2013). Structure
DOI: 10.1016/j.str.2013.06.026   PMID: 23932591

Is your publication missing from the database? Add it here.